Premium
BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY
Author(s) -
Gastinne T.,
Bouabdallah K.,
Moatti H.,
Tessoulin B.,
Shiano del colella J. M.,
Lamy T.,
Casasnovas O.,
Borel C.,
Stamatoullas A.,
Gac A. C.,
Chaoui D.,
Feugier P.,
Delmer A.,
Bonnet C.,
Fornecker LucM.,
Lazarovici J.,
Bras F.,
Ghesquieres H.,
Meignan M.,
Traverse Glehen A.,
Brice P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.111_2880
Subject(s) - abvd , brentuximab vedotin , medicine , dacarbazine , vinblastine , oncology , stage (stratigraphy) , hodgkin's lymphoma , lymphoma , nuclear medicine , hodgkin lymphoma , chemotherapy , vincristine , cyclophosphamide , paleontology , biology